| An endogenous tumour-promoting ligand of the human aryl hydrocarbon receptor CA Opitz, UM Litzenburger, F Sahm, M Ott, I Tritschler, S Trump, ... Nature 478 (7368), 197-203, 2011 | 1957 | 2011 |
| A vaccine targeting mutant IDH1 induces antitumour immunity T Schumacher, L Bunse, S Pusch, F Sahm, B Wiestler, J Quandt, O Menn, ... Nature 512 (7514), 324-327, 2014 | 804 | 2014 |
| Mutational burden, immune checkpoint expression, and mismatch repair in glioma: implications for immune checkpoint immunotherapy TR Hodges, M Ott, J Xiu, Z Gatalica, J Swensen, S Zhou, JT Huse, ... Neuro-oncology 19 (8), 1047-1057, 2017 | 395 | 2017 |
| Constitutive IDO expression in human cancer is sustained by an autocrine signaling loop involving IL-6, STAT3 and the AHR UM Litzenburger, CA Opitz, F Sahm, KJ Rauschenbach, S Trump, ... Oncotarget 5 (4), 1038, 2014 | 327 | 2014 |
| Osteopontin mediates glioblastoma-associated macrophage infiltration and is a potential therapeutic target J Wei, A Marisetty, B Schrand, K Gabrusiewicz, Y Hashimoto, M Ott, ... The Journal of clinical investigation 129 (1), 137-149, 2019 | 317 | 2019 |
| Immune profiling of human tumors identifies CD73 as a combinatorial target in glioblastoma S Goswami, T Walle, AE Cornish, S Basu, S Anandhan, I Fernandez, ... Nature medicine 26 (1), 39-46, 2020 | 308 | 2020 |
| Glioblastoma stem cell-derived exosomes induce M2 macrophages and PD-L1 expression on human monocytes K Gabrusiewicz, X Li, J Wei, Y Hashimoto, AL Marisetty, M Ott, F Wang, ... Oncoimmunology 7 (4), e1412909, 2018 | 300 | 2018 |
| Pan-mutant IDH1 inhibitor BAY 1436032 for effective treatment of IDH1 mutant astrocytoma in vivo S Pusch, S Krausert, V Fischer, J Balss, M Ott, D Schrimpf, D Capper, ... Acta neuropathologica 133 (4), 629-644, 2017 | 213 | 2017 |
| Immune biology of glioma-associated macrophages and microglia: functional and therapeutic implications J Wei, P Chen, P Gupta, M Ott, D Zamler, C Kassab, KP Bhat, MA Curran, ... Neuro-oncology 22 (2), 180-194, 2020 | 179 | 2020 |
| K27M-mutant histone-3 as a novel target for glioma immunotherapy K Ochs, M Ott, T Bunse, F Sahm, L Bunse, K Deumelandt, JK Sonner, ... Oncoimmunology 6 (7), e1328340, 2017 | 108 | 2017 |
| FGL2 promotes tumor progression in the CNS by suppressing CD103+ dendritic cell differentiation J Yan, Q Zhao, K Gabrusiewicz, LY Kong, X Xia, J Wang, M Ott, J Xu, ... Nature communications 10 (1), 1-15, 2019 | 104 | 2019 |
| The Role and Therapeutic Targeting of JAK/STAT Signaling in Glioblastoma A Ou, M Ott, D Fang, AB Heimberger Cancers 13 (3), 437, 2021 | 99 | 2021 |
| Anti–PD-1 Induces M1 Polarization in the Glioma Microenvironment and Exerts Therapeutic Efficacy in the Absence of CD8 Cytotoxic T Cells G Rao, K Latha, M Ott, A Sabbagh, A Marisetty, X Ling, D Zamler, ... Clinical Cancer Research 26 (17), 4699-4712, 2020 | 97 | 2020 |
| Suppression of TDO‐mediated tryptophan catabolism in glioblastoma cells by a steroid‐responsive FKBP52‐dependent pathway M Ott, UM Litzenburger, KJ Rauschenbach, L Bunse, K Ochs, F Sahm, ... Glia 63 (1), 78-90, 2015 | 68 | 2015 |
| Author correction: Fourier transform infrared microscopy enables guidance of automated mass spectrometry imaging to predefined tissue morphologies JH Rabe, DA Sammour, S Schulz, B Munteanu, M Ott, K Ochs, ... Scientific reports 8 (1), 1-2, 2018 | 67* | 2018 |
| Fourier transform infrared microscopy enables guidance of automated mass spectrometry imaging to predefined tissue morphologies JH Rabe, DA Sammour, S Schulz, B Munteanu, M Ott, K Ochs, ... Scientific reports 8 (1), 1-11, 2018 | 65 | 2018 |
| The stress kinase GCN2 does not mediate suppression of antitumor T cell responses by tryptophan catabolism in experimental melanomas JK Sonner, K Deumelandt, M Ott, CM Thomé, KJ Rauschenbach, ... Oncoimmunology 5 (12), e1240858, 2016 | 64 | 2016 |
| Tryptophan‐2, 3‐dioxygenase is regulated by prostaglandin E2 in malignant glioma via a positive signaling loop involving prostaglandin E receptor‐4 K Ochs, M Ott, KJ Rauschenbach, K Deumelandt, F Sahm, CA Opitz, ... Journal of neurochemistry 136 (6), 1142-1154, 2016 | 62 | 2016 |
| Promotion of glioblastoma cell motility by enhancer of zeste homolog 2 (EZH2) is mediated by AXL receptor kinase M Ott, UM Litzenburger, F Sahm, KJ Rauschenbach, R Tudoran, ... PloS one 7 (10), e47663, 2012 | 59 | 2012 |
| Profiling of patients with glioma reveals the dominant immunosuppressive axis is refractory to immune function restoration M Ott, KH Tomaszowski, A Marisetty, LY Kong, J Wei, M Duna, ... JCI insight 5 (17), 2020 | 57 | 2020 |
